195 related articles for article (PubMed ID: 21772050)
1. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Petrizzi VB; Ricci F; Crugnola M; Spriano M; Spedini P; Ilariucci F; Uziel L; Attolico I; Vismara E; De Blasio A; Zaccaria A; Morra E
Blood; 2011 Oct; 118(15):4079-85. PubMed ID: 21772050
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
3. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Geisler CH; van T' Veer MB; Jurlander J; Walewski J; Tjønnfjord G; Itälä Remes M; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MC; Doorduijn J; Ghidey Alemayehu W; van Oers MH
Blood; 2014 May; 123(21):3255-62. PubMed ID: 24735962
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
7. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
8. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
[TBL] [Abstract][Full Text] [Related]
11. High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Majolino I; Ladetto M; Locasciulli A; Drandi D; Benedetti F; Gallamini A; Chisesi T; De Blasio A; Boccadoro M; Tarella C
Med Oncol; 2006; 23(3):359-68. PubMed ID: 17018893
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
14. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Gritti G; Reda G; Maura F; Piciocchi A; Baldini L; Molica S; Neri A; Cortelezzi A
Leuk Lymphoma; 2012 Mar; 53(3):424-9. PubMed ID: 21919823
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Mauro FR; Molica S; Laurenti L; Cortelezzi A; Carella AM; Zaja F; Chiarenza A; Angrilli F; Nobile F; Marasca R; Musolino C; Brugiatelli M; Piciocchi A; Vignetti M; Fazi P; Gentile G; De Propris MS; Della Starza I; Marinelli M; Chiaretti S; Del Giudice I; Nanni M; Albano F; Cuneo A; Guarini A; Foà R;
Leuk Res; 2014 Feb; 38(2):198-203. PubMed ID: 24314589
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT; Hillmen P; Hellmann A; Robak T; Hughes SG; Trone D; Shannon M; Flinn IW; Byrd JC;
Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
[TBL] [Abstract][Full Text] [Related]
17. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Weidmann E; Hess G; Chow KU; Krause SW; Subklewe M; Kruse J; Weisel KC; Soekler M; Kim SZ; Napieralski S; Rech J; Dreyling M; Jäger E; Mitrou PS
Leuk Lymphoma; 2010 Mar; 51(3):447-55. PubMed ID: 20141439
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
